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Background: French health authorities promoted a study on 553,167 newborns comparing the performances of IRT/DNA and IRT/PAP for CF
newborn screening.
Methods: In parallel to IRT/DNA, PAP was assayed in newborns with IRT N 50 μg/L. Provisional PAP cutoffs at 3.0 μg/L when 50 b IRT b 100 μg/L
and 1.7 μg/L when IRT N 100 were used. Positive newborns were subjected to sweat test. Optimal cutoffs were established by a non-inferiority method.
Results: 95 CF newborns were identiﬁed (83 classical forms (ClF), including 9 meconium ileus (MI), and 12 atypical (mild) forms (AF) Of them,
IRT/DNA identiﬁed 85 (73 ClF including 5 MI and 12 AF). PAP cutoffs at 1.8 μg/L when 50b IRTb100 μg/L and 0.6 μg/L when IRTN100 μg/L
would identify 82 CF: 77 ClF, including 8 MI, and 5 AF. The number of sweat tests was 314 and 1039 in the IRT/DNA and IRT/PAP strategies,
respectively.
Conclusions: Using the optimal cutoffs, the sensitivity of the IRT/PAP strategy would not be inferior to that of IRT/DNA if identiﬁcation of MF is
not required.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Neonatal screening; Cystic ﬁbrosis; PAP; IRT; CFTR; Non-inferiority1. Introduction
Nationwide newborn screening (NBS) of cystic fibrosis (CF)
was implemented in France in 2002 [1]. The screening strategyAbbreviations: CF-NBS, cystic fibrosis newborn screening; IRT, immuno-
reactive trypsinogen; PAP, pancreatitis-associated protein
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1569-1993/$ -see front matter © 2014 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2014.01.004involved immunoreactive trypsinogen (IRT) as first tier, followed
by analysis of a panel of CFTR mutations [2]. Such IRT/DNA
strategy was already in use in several countries [3–5] with good
performances. In 2009, the French “Haute Autorité de Santé”
(HAS) published an audit of the first five years of CF screening in
the country and concluded that performances were indeed good
but that the DNA analysis tier raised some concern. Three
potential problems were underscored: i/informed written consent,
required by French bioethics laws before genetic analysis is
performed, cannot be completely fulfilled in daily practice of a
NBS program, ii/identification of healthy heterozygotes and
atypical (mild) forms of the disease, due in part to the choice ofby Elsevier B.V. All rights reserved.
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which goes beyond the goal of newborn screening and iii/the panel
of mutations is based on frequencies observed in the general
population, which is unfair for ethnic minorities. Based on results
from our team [6,7] and others [8–10] on the use of PAP assay
instead of DNA analysis as second tier in CF screening, the HAS
recommended that a large-scale (N500,000 newborns) study is
conducted to investigate whether the performances of an IRT/PAP
strategy could be optimized to match the performances of IRT/
DNA, without the drawbacks generated by genetic analyses.
We were contacted by the CNAMTS (French National Health
Insurance Fund) to conduct such study, whose results are presented
here. In parallel, another teamwas in charge of comparing the cost-
effectiveness of the two strategies. Their results will be published
elsewhere.
2. Methods
Organization, follow-up and analysis of the results of the study
were placed under the supervision of a steering committee led
by the Association Française pour le Dépistage et la Prévention des
Handicaps de l'Enfant (AFDPHE, the French organization in
charge of newborn screening).
2.1. Study sample
The study was conducted between February 1st., 2010 and
January 31st., 2011 and involved 11 of the 23 French NBS centers.
The centers were located in 8 regions (Bretagne, Ile-de-France,
Lorraine, Midi-Pyrénées, Nord-Pas-de-Calais, Pays de Loire,
Provence-Alpes-Côte d'Azur and Rhône-Alpes) chosen to be
representative of the French population. This study was exempted
from approval by the French National Committee on Informatics
and Freedom (CNIL) since it involved anonymous data.
2.2. Screening strategies
Blood was collected on cards by heel pricking on day 3, as
part of the NBS screening program. Newborns on whom the IRT/
DNA or IRT/PAP protocols could not be performed because the
parents refused the CFTR mutation analysis or because of lack of
blood for PAP assays were excluded from the study.
During the 4-month training period prior to the beginning of
the study, the participating centers introduced the PAP assay into
their practice without significant problem and all laboratories
were fully operative before inclusion started. Quality control was
monitored by pooling results from identical samples assayed in
all laboratories. No significant differences were observed among
laboratories.
2.2.1. The IRT/PAP strategy
When blood IRT concentration at day 3 was ≥50 μg/L, PAP
was assayed in duplicate on eluates from the same screening card,
using an ELISA MucoPAP® kit (Dynabio, France). A 3 mm
diameter punch of Whatman #903 paper was initially supposed to
contain 5 μL blood. The punch being eluted in 150 μL PBS, the
dilution factor of blood was taken as 1/30 and PAP concentrationswere initially calculated using this factor. In fact, the actual blood
volume is 3 μL (Dr G Loeber, personal communication), which
means that the dilution factor is 1/50. A statement describing the
conversion was published on the ISNS website (http://www.
isnsneoscreening.org March 2011). All PAP concentrations were
eventually corrected (multiplication factor = 1.66) and the values
presented here are the corrected ones. Newborns were referred for
sweat testing when PAP ≥ 3 μg/L if 50 μg/L b IRT b 100 μg/L
and PAP ≥ 1.7 μg/L if IRT ≥ 100 μg/L. These cutoffs had been
established in a previous study [7].
Raw data were collected monthly in each center and sent
simultaneously to us and to an independent referee appointed
by the CNAMTS, who performed the statistical analysis (Pr R
Giorgi, Biostatistic team of INSERM UMR 912).
2.2.2. Determination of optimal cutoffs
The first criterion to calculate optimal cutoffs for the IRT/PAP
strategy was the detection rate of CF, the goal being that it should
not be lower than in the IRT/DNA strategy (“non-inferiority”)
[11,12]. This was done considering only the diagnosis of classical
forms of CF, since the presence of meconium ileus at birth
makes the diagnosis of CF, and atypical forms can mostly be
identified by the IRT/DNA strategy. The 95% confidence interval
(CI) of the detection rate obtained with the IRT/DNA strategy was
calculated using the exact method (two-sided, with a 0.05 level of
significance). In comparisonwith IRT/DNA, the IRT/PAP strategy
was considered as non-inferior when the lower limit of the 95% CI
of the estimated detection rate was above the non-inferior limit. As
several PAP cutoffs were likely to result in non-inferiority of the
IRT/PAP strategy, the number of sweat tests performed and the
number of false positives obtained were used as additional criteria
for defining optimum cutoff values for the IRT/PAP strategy.
2.2.3. The IRT/DNA strategy
This strategy (Fig. 1) was in use in France before the study
started. IRT was assayed on blood eluted from screening
cards using a DELFIA assay (PerkinElmer) in 8 centers or a
radioimmunoassay (CisBio) in 3 centers. When IRT concentra-
tions ≥ 55 μg/L, the same sample was assayed again in duplicate.
When themean IRT concentration of the duplicate was≥65 μg/L,
DNA analysis was performed. A kit for detecting 30 mutations in
the CFTR was used (Elucigene™ CF30). When at least one
mutation was detected, a sweat test was performed. When no
mutation was detected, a failsafe procedure was applied to
newborns with IRT ≥ 100 μg/L: a new blood sample was
collected on day 21 for IRT assay, and a sweat test was performed
if IRT21 ≥ 40 μg/L. Sweat tests were conducted according to the
procedure used in each center. When quantitative pilocarpine
iontophoresis was used the threshold was 40 mEq/L for babies
less than 3 months old, and was 60 mEq/L when conductivity
was used. CF newborns were classified in three categories: CF
with meconium ileus, borderline (mild) forms (normal or border-
line sweat test and atypical mutations) and classical forms.
Statistical analyses were performed using the R software,
version 2.14.0 (R Development Core Team. R: A language and
environment for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria; 2011. ISBN 3-900051-07-0, URL:
30 CFTR mutations 
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Fig. 1. French IRT/DNA strategy. d3 IRT: immunoreactive trypsinogen assay on a blood sample taken at day 3. d21: blood sample taken around day 21.
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effectiveness analyses.3. Results
During the 12 months of the study, 553,167 newborns were
screened, among which 252 were eventually excluded. As
a result, the analysis was conducted on data from 552,915
newborns including 8487 newborns with IRT ≥ 50 μg/L. Among
these newborns, CF was confirmed in 95, corresponding to 74
classical forms, 12 atypical forms, and 9 meconium ileus.
These numbers, obtained by combining both strategies, have
been updated 24 months after the end of the study, making
the risk of further false negatives very low. The incidence of
the disease was 1/5950, lower than the incidence observed
in previous years in France. However, the incidence reported
for the whole country in the same period was similar (1/6168,
unpublished data), showing that the sample studied,corresponding to 2/3 of the whole population of newborns in
France, was representative and allowed valid comparison of
the two strategies.3.1. The IRT/PAP strategy
3.1.1. Determination of optimal cutoffs
3.1.1.1. IRT cutoffs. Values of IRT cutoffs used in the study
were based on results of our previous study [7]. Our commitment
being to evaluate the simplest possible screening procedure,
implying that the initial IRT is not controlled before proceeding to
PAP assay (contrary to the French IRT/DNA protocol) we decided
to use an initial cutoff of 50 μg/L which should miss few classical
forms of CF if any, without altering too much specificity. Another
observation from our previous study was that CF newborns with
highest IRT values tended to show lower PAP values than CF
newborns with lower IRT values. A 100 μg/L cutoff discriminated
Table 2
Results of the two screening protocols.
Screening protocol IRT/DNA IRT/PAP
IRT positive 2441 8487
Screening test positive, recalled for ST 313 951
Classical CF 68 69
Classical CF with MI 5 8
Atypical CF 12 5
False positives (negative ST) 228 869
HZ 165
Negative ST after failsafe procedure 63
Test negative 552,602 551,964
Classical CF 6 5
Classical CF with MI 4 1
Atypical CF 0 7
Detection rate (%) 91.9 93.2
PPV (%) 27.1 8.6
Newborns included in the study: n = 552,915.
IRT positive: IRTd3 ≥ 55 μg/L and Ctrl IRT ≥ 65 μg/L (IRT/DNA) or
IRTd3 ≥ 50 μg/L (IRT/PAP).
Screening test positive: IRT/DNA: At least one mutation of the 30 mutation
panel or 0 mutation and IRT d3 ≥ 100 μg/L; IRT/PAP: PAP ≥ 1.8 μg/L if
50 ≤ IRTd3 ≤ 100 μg/L or PAP ≥ 0.6 μg/L if IRTd3 ≥ 100 μg/L (IRT/PAP).
ST = sweat-test; CF = Cystic fibrosis: MI = meconium ileus; PPV = Positive
predictive value.
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to select two optimal PAP cutoffs, one for IRT between 50 and
100 μg/L and one for IRT N 100 μg/L.
3.1.1.2. PAP cutoffs. Table 1 shows the results obtained for
the IRT/PAP strategy when combining the two selected IRT
cutoffs (50 and 100 μg/L) with different PAP cutoff values. As
a result of the non-inferiority analysis, optimal PAP cutoffs
were identified at 1.8 μg/L for IRT values between 50 μg/L
and 100 μg/L and at 0.6 μg/L for IRT values above 100 μg/L.
PAP cutoff values higher than 0.6 were not considered since
two CF newborns with IRT N 100 μg/L had a PAP concentra-
tion at 0.7 μg/L. One can see in Table 1 that raising from 1.8 to
2.0 μg/L the PAP cutoff for newborns with IRT between 50
and 100 μg/L would increase specificity by decreasing the
number of false positive cases, but it would also increase the
risk of missing a CF case because two of the CF newborns
identified in this study had a borderline PAP value at 1.9 μg/L.
3.1.2. The IRT/DNA strategy
The IRT/DNA strategy identified 2435 newborns (0.44% of
the whole population) eligible for DNA testing (Table 2). Out
of them, 2185 (89.7%) had 0 mutation, 165 (6.8%) had one
mutation, and 85 (3.5%) had two mutations. Altogether, the
IRT/DNA strategy led to the identification of 68 newborns with
classical forms of CF and 12 with atypical forms. One of
them, with a classical form of CF, was identified through the
failsafe procedure applied to newborns with 0 mutations and
IRT ≥ 100 μg/L. Five of the 9 newborns with meconium
ileus were positive in screening. Taking into account all forms of
CF, the IRT/DNA strategy led to a detection rate of 89.5% (95%
CI: 81.5%–94.8%). When considering only newborns with
classical forms of CF, the detection rate was 91.9% (95% CI:
83.2%–97.0%). The lower limits of the 95% CIs were used as
limits in analyzing the performances of the IRT/PAP strategy. Six
classical forms of CF were missed with the IRT/DNA strategyTable 1
















1.2 0.6 86.7 1706 0.308 84 7
1.3 0.6 86.7 1502 0.271 84 7
1.4 0.6 86.7 1344 0.243 84 7
1.5 0.6 84.9 1210 0.219 83 6
1.6 0.6 84.9 1111 0.201 83 6
1.7 0.6 84.9 1021 0.184 82 6
1.8 0.6 84.9 951 0.172 82 6
1.9 0.6 84.9 904 0.163 82 6
2.0 0.6 83.2 845 0.152 81 6
⁎ Lower limits of the 95% confidence interval of the detection rate for newborns w
indicate that, with the corresponding cutoffs, the IRT/PAP strategy is statistically
⁎⁎ Classical forms of CF without meconium ileus.
§ Atypical (mild) forms of CF.
$ Classical forms of CF with meconium ileus.(Table 2). If positive cases in the calculation of PPV are newborns
referred for sweat testing, then sweat tests that follow themolecular
biology tier (n = 250) and the fail-safe procedure (n = 64) have to
be taken into account. With these criteria, the PPV was 27.1%
(95% CI: 22.3%–32.3%).3.1.3. Performances of the IRT/PAP strategy
The established cutoffs would generate 951 sweat tests
(0.17% of newborns) and identify 869 false positive cases
(false positive rate among newborns submitted to sweatTP FP FN
ssical 
ms**
AF§ MI$ n Classical 
forms**
AF MI
0 6 8 1622 11 4 6 1
0 6 8 1418 11 4 6 1
0 6 8 1260 11 4 6 1
9 6 8 1127 12 5 6 1
9 6 8 1028 12 5 6 1
9 5 8 939 13 5 7 1
9 5 8 869 13 5 7 1
9 5 8 822 13 5 7 1
8 5 8 764 14 6 7 1
ith classical forms of CF. Values greater than 83.2% (the non-inferior limit)
non-inferior to the current IRT/DNA strategy.
Table 3
False negatives identified in the study.
IRT d3 Ctrl IRT PAP Cl− Mut 1 Mut 2
1 66 68 0.4 80 ΔF508del ΔF508del
2 87.8 106.5 0.5 137 E1104X E1104X
3 93.2 105.8 0.8 82 G91R ΔF508del
4 71.1 56.7 0.3 80.0 ΔF508del ΔF508del
5 67.9 54.4 1.5 99.0 ΔF508del ΔF508del
6 87.1 82.9 4.5 70.0 E1104X D110H
7 61.5 62 5.0 88.0 R553X A455E
8 62.4 63.0 14.6 110.0 2183AANG 907delCins11
9 117.0 81.5 15.6 130.0 S466X S466X
Lines 1–3: false negatives in the IRT/PAP strategy, 6–9: false negatives in the
IRT/DNA strategy, due to mutations not detected by the Elucigene™ CF30, 4–
5: false negatives in both strategies. Ctrl IRT is the mean value of the duplicate
IRT assay run if IRTd3 N 55 μg/L. A Ctrl IRT N 65 μg/L triggers DNA
analysis. IRT and PAP concentrations in μg/L, Cl− in mEq/L.
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using these cutoffs is statistically non-inferior to the current IRT/
DNA strategy and would lead to the identification of 69 newborns
with classical forms of CF and 5 newborns with atypical forms.
Eight of the 9 newborns with meconium ileus would be
positive (Table 2). Such IRT/PAP strategy would also generate
12 false negative tests results, among which 7 newborns with
atypical forms of CF (Table 3). When considering all forms of
CF, the detection rate would be 86.3% (95% CI: 77.7%–92.5%).
Considering only newborns with classical forms of CF the
detection rate would be 93.2% (95% CI: 84.9%–97.8%). With
the same criteria as for IRT/DNA, the PPV of IRT/PAP would be
8.6% (95% CI: 6.9%–10.6%).
Details on the newborns with classical forms of CF missed
by either strategy are given in Table 2. Two newborns would be
missed by both strategies.
It is noteworthy that raising the lower IRT cutoff from 50 to
55 μg/L would decrease the number of sweat tests from 951 to
797. The number of false positives would decrease to 715.
The detection rate of classical forms of CF would be identical.
However, one of the classical forms of CF was quite borderline
(IRT = 55 μg/L) suggesting that such cutoff is not totally safe.
4. Discussion
Since CF newborn screening became available with the
introduction of IRT assay on Guthrie cards, the most important
improvement has been the introduction of CFTR mutation
analysis, made possible by the transfer to the screening laboratories
of molecular biology techniques. Many countries in which the
disease is frequent, such as Australia [3], the USA [4] and France
[2] have implemented the IRT/DNA strategy with very good
performances. Commercial kits presently available allow detection
of about 30 mutations, selected as the most frequent ones in the
Western countries that initiated CF screening. As a result, lower
detection rates are expected in non-European-derived populations
[13]. To improve the strategy, mutation frequencies in each ethnic
group must be determined beforehand to complete the mutation
panel. However, increasing the number of investigated muta-
tions will increase the number of identified heterozygotes.Such drawbacks curb the expanding of CF newborn screening.
Furthermore, the use of genetic markers is prohibited in some
countries. In other countries, there are ethical concerns about
detection of atypical forms of CF [14] and the relevance of
informing parents about carrier status [15] has resulted in en-
couraging research on non-genetic neonatal markers. This is the
case in France. Previous studies have shown that PAP assay
might replace the DNA tier of CF screening while keeping similar
detection rates and a manageable recall of 0.25% of newborns for
sweat testing [7]. However, switching from IRT/DNA, a strategy
in practice since 2002, to IRT/PAP required that unquestionable
evidence is produced. In order to gather the required information,
French Health authorities promoted this study comparing IRT/
DNA and IRT/PAP strategies on more than 500,000 newborns.
Amere prospective study with cutoff values decided in advance
was not possible because, due to an evolution in the PAP assay kit
involving a change from polyclonal to monoclonal antibodies for
antigen capture and revelation, it was known that the PAP cutoffs
previously established [7] would have to be adjusted. Hence, the
first step of the study was to determine optimal PAP cutoffs, with
sensitivity as first criterion, using a statistical approach based on
non-inferiority, i.e. looking for a performance of IRT/PAP non-
inferior to that of the current IRT/DNA strategy. To our
knowledge, the present study is the first that used a statistical
approach based on non-inferiority [11,12] to determine optimal
cutoffs for CF-NBS.
Based on PAP cutoffs of 1.8 μg/L for 50 b IRT b 100 μg/L
and 0.6 μg/L for IRT N 100 μg/l, sensitivities of both strategies
are similar and the question is whether the specificity of IRT/
PAP is acceptable. Percentage of newborns recalled for sweat
testing was 0.17%, lower than the 0.25% expected from our
previous study but about three times higher than in the IRT/
DNA protocol. This percentage would trigger less than 1 sweat
testing a week for each CF pediatric center in France. However,
one must underscore that acceptability is a relative concept,
highly dependent on practical, ethical and economic criteria.
This is why the meaning of comparing the performances of
the IRT/PAP strategy to those published with other strategies is
limited. For instance, one of the advantages of PAP is the
suppression of carrier detection and the much smaller number of
mild forms identified; how would IRT/PAP compare with the
strategy of the Massachusetts screening program [16] whose
results, on more than 300,000 births, show very good sensitivity of
IRT/DNA (2 CF missed among 112) but perform mutation
analysis in 5% of newborns (compared to ~0.5% in the French
algorithm) and sweat testing in all babies with at least one
mutation, plus those with 0 mutation but IRT in the upper 0.02
percentile? Clearly, the IRT/PAP protocol is efficient when
certain criteria are retained, and its implementation should be of
interest in certain countries, not all. A recent report [17] compared
three IRT/PAP protocols tested in Germany, Poland and Czech
Republic. Their conclusion was that using IRT/PAP for CF
screening is a good choice. They recommended using an IRT
cutoff at the 99th percentile and a failsafe at the 99.9th percentile.
The present study involved a comparison of IRT/DNA- and
IRT/PAP-based CF-NBS, but IRT/PAP/DNA strategies have been
recently proposed [9,17], in order to find the best compromise
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disease and the number of sweat tests, two large scale studies
conducted in the Netherlands and the Czech Republic [9,17,18]
compared IRT/PAP- and IRT/PAP/DNA-based CF-NBS. Results
show that the two strategies perform equally well, although the
Czech study reported a slightly lower detection rate for IRT/PAP/
DNA [18]. Both studies clearly showed that using the 30
mutation panel in newborns with high IRT and PAP identified
most but not all CF babies and that a further screening step had to
be considered. The Czech chose sweat testing of newborns with 1
mutation and the Dutch chose as failsafe to sequence all exons
of the CFTR gene in newborns with 1 mutation or 0 mutation
if IRT N 100 μg/L.With the incidence of CF observed in France,
applying the Dutch protocol to our study would add 1 false
negative corresponding to an affected newborn with none of the
mutations included in the kit Elucigene™ CF30 but with an
IRT b 100 μg/L. Clearly, each screening center that starts an
IRT/PAP strategy uses at the beginning published cutoffs, then
adapts the strategy to the local situation after sufficient data is
analyzed.
In conclusion, compared to IRT/DNA, the IRT/PAP strategy
can have a similar detection rate of classical forms of CF while
detecting a smaller number of mild forms. Switching from IRT/
DNA to IRT/PAP should not raise any significant technical or
practical problem in the laboratories in charge with PAP. The
IRT/PAP strategy could be the best choice in countries with
important ethnic diversity. In countries already using the IRT/
DNA strategy, switching to IRT/PAP/DNA would maintain the
detection of carriers of common CF mutations at some level,
but the number of sweat tests would be greatly diminished. In
France, the IRT/PAP/DNA strategy would only slightly differ
from the IRT/DNA strategy. The only change would be that the
control IRT assay, run in duplicate in newborns with an initial
IRT N 55 μg/L, on which is decided mutation analysis if its
mean value is N65 μg/L is replaced by a PAP assay in duplicate.
After mutation analysis, an alternative to the failsafe chosen in the
Netherlands (sequencing) would be sweat testing, on the same
criteria.
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